Fortress Biotech, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Asset Purchase and Merger Agreements (Narrative) (Details)

v3.25.2

Asset Purchase and Merger Agreements (Narrative) (Details)			3 Months Ended		6 Months Ended		30 Months Ended
	Mar. 09, 2025	Jul. 15, 2024 USD ($) director	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($)
Urica
Percentage of equity to be held		35.00%
Urica \| Asset Purchase, Royalty And Related Agreements With Crystalis
Consideration Transferred		$ 6,400,000
Percentage of royalty on future net sales		3.00%
Urica's equity position		15.00%
Capitalization in equity securities		$ 150,000,000
Reimbursement for clinical costs		$ 600,000
Number of directors \| director		1
Amount of minimum qualified financing required		$ 120,000,000
Assets Sold under Agreements to Repurchase, Accretion Expense			$ (100,000)	$ 0	$ 600,000	$ 0
Avenue \| InvaGen \| Avenue Share Repurchase Agreement
Percentage of contingent fee payable			7.50%		7.50%		7.50%
Contingent fee payable from proceeds of future financing			$ 4,000,000		$ 4,000,000		$ 4,000,000
Payments of milestones			$ 0	$ 300,000	$ 200,000	$ 600,000	$ 1,400,000
Checkpoint
Percentage of royalty on future net sales	2.50%

- Definition

Percentage of common stock issued to the company, pursuant to asset acquisition arrangement.

+ References

No definition available.

+ Details

Name:	fbio_AssetAcquisitionPercentageOfCommonStockIssued
Namespace Prefix:	fbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of accretion expense recognized under assets sold under repurchase agreements for the passage of time, typically for liabilities, that have been discounted to their net present values.

+ References

No definition available.

+ Details

Name:	fbio_AssetsSoldUnderAgreementsToRepurchaseAccretionExpense
Namespace Prefix:	fbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents maximum amount of equity securities to be raised by the company.

+ References

No definition available.

+ Details

Name:	fbio_MaximumAmountOfEquitySecuritiesToBeRaised
Namespace Prefix:	fbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of directors of the board of directors of the counterparty, that the company has right to appoint, pursuant to an agreement.

+ References

No definition available.

+ Details

Name:	fbio_NumberOfDirectorsThatCompanyHasRightToAppoint
Namespace Prefix:	fbio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

It represents payments of milestone.

+ References

No definition available.

+ Details

Name:	fbio_PaymentsOfMilestone
Namespace Prefix:	fbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of royalty on future net sales granted to the company.

+ References

No definition available.

+ Details

Name:	fbio_PercentageOfRoyaltyOnFutureNetSales
Namespace Prefix:	fbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of contingent fee payable on the proceeds of future financings.

+ References

No definition available.

+ Details

Name:	fbio_StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsAmount
Namespace Prefix:	fbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage of contingent fee payable on the proceeds of future financings.

+ References

No definition available.

+ Details

Name:	fbio_StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsPercent
Namespace Prefix:	fbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Threshold percentage of fully diluted equity capitalization position in counterparty, to be held by company, until specified amount of equity securities is raised by such counterparty.

+ References

No definition available.

+ Details

Name:	fbio_ThresholdPercentageOfFullyDilutedEquityCapitalizationPosition
Namespace Prefix:	fbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of minimum qualified financing required for the expiry of repurchase option

+ References

No definition available.

+ Details

Name:	fbio_ThresholdQualifiedFinancingForExpiryOfRepurchaseOption
Namespace Prefix:	fbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479908/805-50-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=fbio_AssetPurchaseRoyaltyAndRelatedAgreementsWithCrystalisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=fbio_InvagenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=fbio_AvenueShareRepurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: